NCT03808272CompletedNot Applicable
A Prospective, Multi-center, Single-arm Study to Evaluate the Safety and Efficacy of AXIOS Stent and Electrocautery-enhanced Delivery System in Chinese Patients With Pancreatic Pseudocyst and Walled-off Necrosis(WON)
Boston Scientific Corporation1 site in 1 country31 target enrollmentStarted: April 17, 2019Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 31
- Locations
- 1
- Primary Endpoint
- Technical success rate
Study Overview
Brief Summary
To study the safety and effectiveness of the AXIOS Stent with Electrocautery Enhanced Delivery System for endoscopic trans enteric drainage of pancreatic pseudocyst and walled-off necrosis in Chinese population, to support the regulatory approval by CFDA
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age between 18 and 75 years old(including 18 and 75 years old)
- •Eligible for endoscopic intervention
- •Acceptable candidate for endoscopic transluminal pancreatic pseudocyst drainage
- •Diagnostic as symptomatic pancreatic pseudocysts ≥ 6cm in maximum diameter and walled-off necrosis ≥ 6cm in maximum diameter with ≥ 70% fluid content that are adherent to the gastric or bowel wall
- •Patient understands the study requirements and the treatment procedures and provides written Informed Consent.
- •Patient is willing to comply with all specified follow-up evaluations, including willingness to undergo a pre/post CT imaging study.
Exclusion Criteria
- •<18 or >75 years of age
- •pseudocysts or walled-off necrosis which require nasocystic drainage,or<6cm in maximum diameter, or walled-off necrosis < 70% fluid content
- •The fluid collection to be drained is an immature pseudocyst
- •The fluid collection to be drained is a cystic neoplasm
- •The fluid collection to be drained is a pseudoaneurysm
- •The fluid collection to be drained is a duplication cyst
- •The fluid collection to be drained is a non-inflammatory fluid collection
- •There is more than one pseudocyst requiring drainage
- •Abnormal coagulation: INR > 1.5 and not correctable presence of a bleeding disorder; platelets < 50,000/mm3
- •Altered anatomy that precludes the physician's ability to deliver the stent (decision on a case by case basis).
- •Intervening gastric varices or vessels within a one centimeter radius of the needle (visible using endoscopy or endoscopic ultrasound)
- •Any prior true anaphylactic reaction to contrast agents, nitinol (nickel titanium), silicone or any other materials contacting the patient.
- •Female of childbearing potential with a positive pregnancy test prior to the procedure or intends to become pregnant during the study.
- •Currently participating in another investigational drug of device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study.
Outcomes
Primary Outcomes
Technical success rate
Time Frame: 28± 7 days post stent placement
defined as: placement of the AXIOS stent using the Electrocautery Enhanced AXIOS delivery system and removal of the AXIOS stent using a standard method: such as endoscopic snare or forceps.
Clinical success rate
Time Frame: 28± 7 days post stent placement
defined as: at least a 50% decrease in pseudocyst's maximum diameter, based on radiographic analysis
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
AXIOS™ for Gallbladder Drainage as an Alternative to Percutaneous Drainage IDECholecystitis, AcuteNCT03767881Boston Scientific Corporation30
Completed
Not Applicable
AXIOS Stent With Electrocautery Enhanced Delivery SystemPancreatic Pseudocyst(s)NCT02146352Xlumena, Inc.30
Completed
Not Applicable
AXIOS Stent & Delivery System StudyPancreatic Pseudocyst(s)NCT01419769Xlumena, Inc.30
Completed
Phase 3
Safety and Efficacy of Express LD to Treat Stenosed or Occlusive Atherosclerotic Disease in Iliac ArteriesIntermittent ClaudicationAtherosclerotic DiseaseThrombosisArterial Occlusive DiseaseNCT00352222Boston Scientific Corporation150
Completed
Phase 4
Prospective, Single-arm, Multicenter Study for Evaluation the Safety and Effectiveness of the ALEX Stent in a Real-world Setting of Percutaneous Coronary Interventions in Patients With Coronary Heart DiseaseMyocardial InfarctionUnstable AnginaStable AnginaNCT01637012Balton Sp.zo.o.60